

December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2008-004467-19/ Novartis Protocol ID CAMN107AHU01

*An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis, previously enrolled in and having completed ENACT (CAMN107A2109) trial in Hungary.*

Trial CAMN107AHU01 was cancelled with no patient enrollment and as such, no results will be reported.